Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.55 |
| ▸ | GRK2 | P25098 | 9/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | PRKCA | P17252 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | F3 | P13726 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5116727 | 0.79 | ROCK2 (0.68) | ALDH1A1ROCK2GRK2KMT2APRKCA | |
| SCHEMBL5116756 | 0.78 | ROCK2 (0.59) | MAPTROCK2GRK2PRKCACYP3A4 | |
| SCHEMBL5122272 | 0.78 | ROCK2 (0.76) | ALDH1A1MAPTROCK2GRK2PRKCA | |
| SCHEMBL5117843 | 0.75 | ROCK2 (0.61) | ALDH1A1ROCK2GRK2PRKCAROCK1 | |
| SCHEMBL4788582 | 0.72 | ROCK2 (0.62) | ROCK2GRK2PRKCA | |
| SCHEMBL13376954 | 0.72 | MAPK8 (0.49) | ALDH1A1MAPTROCK2GRK2KMT2A | |
| SCHEMBL5116238 | 0.72 | ROCK2 (0.61) | ROCK2GRK2PRKCAROCK1 | |
| SCHEMBL4788257 | 0.71 | ROCK2 (0.56) | ROCK2GRK2PRKCACYP3A4CYP2D6 | |
| SCHEMBL4788086 | 0.70 | GRK2 (0.49) | ROCK2GRK2PRKCA | |
| SCHEMBL4789976 | 0.70 | ROCK2 (0.60) | MAPTROCK2GRK2KMT2APRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008011557-A2 | HETEROARYL INHIBITORS OF RHO KINASE | BORCHARDT ALLEN J (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011557-A2 | HETEROARYL INHIBITORS OF RHO KINASE | BORCHARDT ALLEN J (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | Borchardt, Allen (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | Borchardt, Allen (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | Borchardt, Allen (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | ROCK1, ROCK2, RHOA | ALDH1A1 3968/4885MAPT 1499/4885ROCK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.